FOURIER (TIMI 59) / EBBINGHAUS

FOURIER (TIMI 59) is a double-blind, randomized, placebo-controlled, multicenter study assessing the Impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease.

EBBINGHAUS is a cognitive study of patients enrolled in the FOURIER trial.

SLIDE SETS

FOURIER Main Results (Sabatine, ACC 2017) 

EBBINGHAUS Main Results (Giugliano, ACC 2017)

BWH Cardiovascular Grand Rounds - April 6, 2017

Achieved LDL-C  (Giugliano, ESC 2017)

Stroke (Pederson, ESC 2017)

Diabetes (Sabatine, EASD 2017)

PAD (Bonaca, AHA 2017)

MI Subgroup (Sabatine, AHA 2017)

Total Events (Murphy, AHA 2017)

MI Size and Type (Wiviott, AHA 2017)

Risk Score (Bohula, AHA 2017)

Key Study Publications

Sabatine MS,  Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SW, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 2017 NEJM, Epub before print. 

LINK TO CLINICALTRIALS.GOV